05 feb: PANDORA LEVERER PÅ DE FINANSIELLE FORVENTNINGER OG PÅBEGYNDER TO-..
05 feb: Årsrapport 2018
05-02-2019 02:40:20

Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018

Financial report for the period 1 January to 31 December 2018

Lundbeck realized 8% growth in revenue (local currencies)

 and 48% growth in EPS in 2018

HIGHLIGHTS

  • Revenue reached DKK 18,117 million in 2018 representing an increase of 5% (8% in local currencies) compared to 2017
    • Revenue of Abilify Maintena® increased 20% to DKK 1,595 million (23% in local currencies)
    • Revenue of Brintellix®/Trintellix® increased 31% to DKK 2,182 million (37% in local currencies)
    • Revenue of Northera® increased 10% to DKK 1,806 million (15% in local currency)
    • Revenue of Onfi® increased 5% to DKK 3,165 million (12% in local currency)
    • Revenue of Rexulti® increased 38% to DKK 1,723 million (44% in local currencies)
    • Revenue in North America increased 1% to DKK 10,743 million (6% in local currencies)
    • Revenue in International Markets increased 3% to DKK 3,500 million (10% in local currencies)
    • Revenue in Europe increased 6% to DKK 2,970 million (6% in local currencies)
  • EBIT increased 20% to DKK 5,301 million in 2018 compared to DKK 4,408 million in 2017 and the EBIT margin reached 29.3% compared to 25.6% the year before
  • EPS grew 48% to DKK 19.66 in the period compared to DKK 13.28 the year before
  • Free cash flow reached DKK 3,074 million representing an increase of 39%, and the net cash position improved to DKK 6,635 million compared to DKK 3,677 million the year before
  • Lundbeck and Otsuka received positive headline results from a proof of concept study investigating the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder
  • For 2019, Lundbeck expects revenue to reach DKK 16.1–16.7 billion and EBIT to reach DKK 4.2–4.6 billion
  • The Board of Directors proposes to pay a dividend of DKK 12.00 per share, equal to a pay-out ratio of 61%
  • Lundbeck’s revised strategy, Expand and Invest to Grow, envisions expanded operating space in brain diseases, rebuilding the R&D pipeline through external innovation while maintaining focus on profitability aspiring to an EBIT-margin of at least 25%
  • Following Expand and Invest to Grow, Lundbeck will see increased capital needs related to our strategic initiatives and therefore, revises the dividend policy from the current range of 60-80% of net profit to a range of 30-60% of net profit from 2019 onwards

In connection with the financial report, Lundbeck’s President and CEO Deborah Dunsire said:

“Lundbeck has delivered its best financial result ever and has more than achieved the financial targets set in 2016. Our goal now is to achieve sustainable, profitable growth through maximizing our neuroscience platform and strengthening our pipeline across all phases. We have conducted a strategic review and some of the elements include broadening the disease focus within brain health, as well as accelerating our internal pipeline and accessing external innovation to capitalize on our competitive edge”.

DKK million

FY 2018

FY 2017

Growth

Reported Revenue

18,117

17,234

5%

Reported EBIT

5,301

4,408

20%

Reported EPS

19.66

13.28

48%

Reported EBIT margin

29.3%

25.6%

-

 

 

 

 

Core Revenue*

18,117

17,234

5%

Core EBIT*

6,158

5,115

20%

Core EPS*

23.71

16.50

44%

Core EBIT margin*

34.0%

29.7%

-

       *For definition of the measures “Core Revenue”, “Core EBIT” and “Core EPS”, see note 4 Core reporting

Attachment

logo.jpg

Relateret indhold
08 mar - 
Lundbeck henter ny direktør til strategi og forretnings..
05 mar - 
Tirsdagens aktier: Lundbeck og Novozymes i top på nyhed..
19 feb - 
Tirsdagens aktier: William Demant sendt i kulkælderen e..
Relateret debat
21 feb - 
Hej, det går godt med kursen. Så hen mod 26..
14 feb - 
Synes også der er en høj fejlrate hos Lundbæk. De blive..
14 feb - 
hvornår har de sidst haft succes med deres forskn..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Recessionsfrygt i obligationsmarkedet

22-03-2019 15:08:12
Rentemarkederne har i dag sendt flere signaler, som analytikere betegner som klare signaler om lavere vækst og måske endda recession.Således faldt den tyske 10-årige statsobligationsrente i dag under 0 pct., hvilket afspejler investorernes frygt for den europæiske vækst. Tal, der viser indkøbschefernes forventninger til fremtiden, de såkaldte PMI-tal, faldt kraftigere end ventet i marts i flere eu..

Tysk 10-års rente falder under 0 pct. – "Gassen er gået af ballonen"

Relaterede nyheder
22-03-2019 11:26:06
De tyske PMI-tal, som i dag blev i dag offentliggjort, faldt til 44,7 fra 47,6 og rammer dermed laveste niveau siden september 2012. I en kommentar til Euroinvestor udtaler makroanalytiker i Sydbank, Mathias Rømer Sproegel: "Dagens læsning af de tyske PMI’er var ikke rar læsning for investorerne. Bekymringer om Brexit, den globale handelskrig mellem USA og Kina samt fortsat store problemer i den t..

Lars Christensens Verden - Episode 12: Bankernes rolle i samfundet

Relaterede nyheder
22-03-2019 07:12:24
I ”Lars Christensens Verden” går økonom og chefredaktør på Euroinvestor Lars Christensen bag om markedet i samtaler med professionelle markedsaktører, kommentatorer og økonomiske og finansielle forskere. Det handler om, hvad det i virkeligheden er, der driver de finansielle markeder. Det er ikke investeringsråd, men mottoet er, at den, der ved mest, tjener mest. Det leveres alt sammen med humor og..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo udbyttemilliarder kan trække C25 i rødt
2
Middag: Sydbank og Vestas til bunds i rødt marked
3
Fredagens aktier: Vestas og Sydbank sank i surt marked
4
Recessionsfrygt i obligationsmarkedet
5
Genmab-partner søger om udvidet brug af Darzalex i Europa

Relaterede aktiekurser

Lundbeck A/S 298,90 -1,1% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. marts 2019 07:27:48
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190320.1 - EUROWEB1 - 2019-03-23 07:27:48 - 2019-03-23 07:27:48 - 1 - Website: OKAY